Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 7/20 | 0.46 |
| ▸ | CES1 | P23141 | 5/20 | 0.46 |
| ▸ | CES2 | O00748 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | SMPD1 | P17405 | 4/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | FDPS | P14324 | 1/20 | 0.43 |
| ▸ | LAP3 | P28838 | 1/20 | 0.43 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.43 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.43 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.43 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.43 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2783090 | 1.00 | FAAH (0.46) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL25868 | 1.00 | FAAH (0.46) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL3792251 | 0.91 | FAAH (0.54) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL1367614 | 0.91 | FAAH (0.54) | FAAHCES1CES2MEN1CYP1A2 | |
| Hydrochloric Acid SCHEMBL6560336 | 0.77 | FAAH (0.50) | FAAHCES1CES2MEN1CYP1A2 | |
| Phosphoric Acid SCHEMBL5312301 | 0.77 | FAAH (0.53) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL7865628 | 0.74 | FAAH (0.43) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL15323484 | 0.74 | FDPS (0.56) | SMPD1FDPSLAP3LPAR1LPAR3 | |
| SCHEMBL16493550 | 0.73 | FAAH (0.46) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL14629803 | 0.73 | FAAH (0.46) | FAAHCES1CES2MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025125241-A1 | PHARMACEUTICAL COMPOSITION | COEGIN PHARMA AB (SE) | 2025-06-19 | — | — | WO | claimed |
| EP-4132469-B1 | ADMINISTRATION OF MTOR INHIBITORS INTO THE CENTRAL NERVOUS SYSTEM | DOLCETTA DIEGO (IT) | 2023-11-29 | — | — | EP | claimed |
| US-20230133251-A1 | ADMINISTRATION OF mTOR INHIBITORS INTO THE CENTRAL NERVOUS SYSTEM | DOLCETTA DIEGO (IT) | 2023-05-04 | — | — | US | claimed |
| EP-4132469-A1 | ADMINISTRATION OF MTOR INHIBITORS INTO THE CENTRAL NERVOUS SYSTEM | Dolcetta, Diego (IT) | 2023-02-15 | — | — | EP | claimed |
| US-20220287944-A1 | SILK PERSONAL CARE COMPOSITIONS | EVOLVED BY NATURE INC (US) | 2022-09-15 | — | — | US | claimed |
| US-20220218878-A1 | CONTROLLED HEAT DELIVERY COMPOSITIONS | BAMBU VAULT LLC (US) | 2022-07-14 | — | — | US | claimed |
| EP-4017537-A1 | SILK PERSONAL CARE COMPOSITIONS | Evolved by Nature, Inc. (US) | 2022-06-29 | — | — | EP | claimed |
| WO-2021035087-A1 | SILK PERSONAL CARE COMPOSITIONS | EVOLVED BY NATURE, INC. (US) | 2021-02-25 | — | — | WO | claimed |
| WO-2020243047-A1 | CONTROLLED HEAT DELIVERY COMPOSITIONS | BAMBU VAULT LLC (US) | 2020-12-03 | — | — | WO | claimed |
| US-20150132369-A1 | NANOLIPOSOMAL CYCLOSORIN FORMULATIONS FOR IMMUNOSUPPRESION AND METHODS FOR THE PRODUCTION THEREOF | Exir Nano Sina Company (IR) | 2015-05-14 | — | — | US | claimed |
| WO-2009031911-A1 | CATIONIC LIPOSOME CARRIER FOR GENETIC DRUGS | UNIWERSYTET WROCLAWSKI (PL) | 2009-03-12 | — | — | WO | claimed |
| EP-4737439-A1 | IONIZABLE LIPID AND USE THEREOF | Axter Therapeutics (Beijing) Co., Ltd. (CN) | 2026-05-06 | — | — | EP | disclosed |
| US-12569439-B2 | Bottom-up assembly of synthetic extracellular vesicles | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2026-03-10 | — | — | US | disclosed |
| US-20250257409-A1 | COMPOSITIONS AND METHODS FOR THERAPEUTICS PRESCREENING | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2025-08-14 | — | — | US | disclosed |
| US-12344899-B2 | Compositions and methods for therapeutics prescreening | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2025-07-01 | — | — | US | disclosed |
| WO-2009031911-A1 | CATIONIC LIPOSOME CARRIER FOR GENETIC DRUGS | UNIWERSYTET WROCLAWSKI (PL) | 2009-03-12 | — | — | WO | disclosed |
| WO-2008075192-A2 | TARGETING AND THERAPEUTIC COMPOUNDS AND GAS-FILLED MICROVESICLES COMPRISING SAID COM OUNDS | BRACCO INTERNATIONAL BV (NL) | 2008-06-26 | — | — | WO | disclosed |
| EP-1906924-A1 | BONE MARROW-DIRECTING DRUG DELIVERY MATERIALS AND THEIR APPLICATIONS | WASEDA UNIVERSITY (JP) | 2008-04-09 | — | — | EP | disclosed |
| WO-2006132388-A1 | BONE MARROW-DIRECTING DRUG DELIVERY MATERIALS AND THEIR APPLICATIONS | WASEDA UNIVERSITY (JP) | 2006-12-14 | — | — | WO | disclosed |
| US-20050186264-A1 | Targeting moiety specific for cellular adhesion molecules expressed on endothelial cells conjugated to biomolecular carrier; cyclic Arg-Gly-Asp-D-Phe-Cys sequence conjugated to liposome and a drug encapsulated; radiotherapy; cancer | BOARD OF TRUSTEES OF OHIO UNIVERSITY, THE | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569439-B2 | Bottom-up assembly of synthetic extracellular vesicles | EXOSC10, PLTP, EXOSC9 | FAAH 1698/4885CES1 3436/4885CES2 4020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.